Patent ID: 8841319

Claim:
A method of treating leukemia in a subject in need of such treatment, or of preventing leukemia by arresting or reversing the progression of pre-leukemic cells to leukemic cell in a subject at risk of developing leukemia, wherein the method comprises administering an effective amount of a compound of formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of the compound of formula I or of the physiologically acceptable salt thereof, to the subject wherein R 1 is H, C 1 -C 6 -alkyl, phenyl-C 1 -C 4 -alkyl or phenyl, R 2 is a phenyl group which is substituted with 2 or 3 C 1 -C 6 -alkoxy groups and R 3 is indolyl or azaindolyl which may carry one or two substituents independently selected from C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, phenyl, OH, halogen, NH 2 , C 1 -C 6 -alkylamino, di-C 1 -C 6 -alkylamino, heteroaryl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S, and heterocyclyl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S, wherein the leukemia is characterized by leukemic cells which (i) show enhanced expression of FLT3, compared to non-malignant cells of the same cell type, or (ii) are positive for one or more than one activating mutation of the FLT3 gene.